In the latest trading session, 0.42 million Autolus Therapeutics plc ADR (NASDAQ:AUTL) shares changed hands as the company’s beta touched 2.03. With the company’s most recent per share price at $3.59 changed hands at -$0.04 or -1.24% at last look, the market valuation stands at $953.79M. AUTL’s current price is a discount, trading about -107.52% off its 52-week high of $7.45. The share price had its 52-week low at $2.01, which suggests the last value was 44.01% up since then. When we look at Autolus Therapeutics plc ADR’s average trading volume, we note the 10-day average is 0.76 million shares, with the 3-month average coming to 923.38K.
Analysts gave the Autolus Therapeutics plc ADR (AUTL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.44. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AUTL as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Autolus Therapeutics plc ADR’s EPS for the current quarter is expected to be -0.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Instantly AUTL was in red as seen in intraday trades today. With action 2.14%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -44.33%, with the 5-day performance at 2.14% in the green. However, in the 30-day time frame, Autolus Therapeutics plc ADR (NASDAQ:AUTL) is -8.78% down. Looking at the short shares, we see there were 10.73 million shares sold at short interest cover period of 17.85 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9.5, meaning bulls need an upside of 62.21% from its recent market value. According to analyst projections, AUTL’s forecast low is 8 with 11 as the target high. To hit the forecast high, the stock’s price needs a -206.41% plunge from its current level, while the stock would need to soar -122.84% for it to hit the projected low.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
Data shows that the Autolus Therapeutics plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -34.94% over the past 6 months, a 30.00% in annual growth rate that is considerably higher than the industry average of 17.80%. Year-over-year growth is forecast to reach 796.90% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 130k. 6 analysts are of the opinion that Autolus Therapeutics plc ADR’s revenue for the current quarter will be 110k. The company’s revenue for the corresponding quarters a year ago was 406k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -68.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 3.32%. The 2024 estimates are for Autolus Therapeutics plc ADR earnings to increase by 31.59%.
Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s Major holders
BLACKSTONE INC. holds the second largest percentage of outstanding shares, with 9.2207% or 20.49 million shares worth $71.29 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jul 31, 2024 were Vanguard Specialized-Health Care Fund and Fidelity Advisor Biotechnology Fund. With 18.9 shares estimated at $67.74 million under it, the former controlled 7.10% of total outstanding shares. On the other hand, Fidelity Advisor Biotechnology Fund held about 1.13% of the shares, roughly 3.01 shares worth around $10.79 million.
